Sat.Jun 25, 2022 - Fri.Jul 01, 2022

article thumbnail

Discovery Park announced as location of new Barclays Eagle Lab

Drug Discovery Today

Barclays has selected Discovery Park in Kent as the home for its latest Eagle Lab which will open later this year. The lab will help facilitate collaboration between the Life Sciences and Technology sectors, with the aim of driving development of a community base focused on clean energy, agri-tech and addressing future challenges in healthcare.

Science 113
article thumbnail

New patent for Teva Branded drug AUSTEDO

Drug Patent Watch

Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are seven…. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 93
article thumbnail

Drug Channels News Roundup, June 2022: Drug Spending in 2021, PBM Exclusions, Employers vs. Rebates, GoodRx Questions, and More Prior Authorization Humor

Drug Channels

I can’t recall any period in my life when our country has been so divided and polarized. Through the Drug Channels Institute, I strive to provide you with fact-based and balanced coverage—along with links to source materials so you can make up your own mind. So before you launch your July 4 festivities and/or a civil war, Drug Channels humbly offers some data fireworks for our troubled nation: More evidence of slow growth in drug spending for 2021 Fresh data on skyrocketing PBM formulary exclusi

article thumbnail

Optimizing the digitization of tech transfer and scale-up for Pharma 4.0

Pharma Manufacturing

Advanced digital thread and technology transfer capabilities can help pharma reap the benefits of its processes

75
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Beyond the pill | Moving towards value-added services

Altus Drug Development

A focus on customers has always been one of the main pillars of the pharmaceutical industry. However, this is often narrowed down to the creation of product-centric marketing strategies with a strong customer orientation. While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. The integration of value-added services and strategies provides a new perspective on patient care.

article thumbnail

New patent for Abbvie Inc drug ORILISSA

Drug Patent Watch

Annual Drug Patent Expirations for ORILISSA Orilissa is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Abbvie Inc drug ORILISSA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 91

More Trending

article thumbnail

The Progress of Precision Medicine in Immuno-Oncology

Crown Bioscience

Precision medicine and immunotherapy continue to top the list as two of the hottest areas in cancer research. In this blog post we explore how immuno-oncology can draw from precision medicine to create more personalized cancer therapies to enhance their safety and efficacy. Read on to review how ICIs, neoantigen vaccines and adoptive cell therapies, including CAR-T, CAR-NK, CAR-M, TCR-T and TIL therapies, are advancing this remarkable field of science and medicine.

article thumbnail

Common Pitfalls in Preparing an IND Application

Advarra

As a drug successfully makes it through the development process, sponsors will inevitably need to submit a new drug application (NDA) to the Food and Drug Administration (FDA). While it may seem like a straightforward process to some, there’s room for many elements to be missed as sponsors prepare for the application submission. Failure to Have a Pre-Investigational New Drug (IND) Meeting.

FDA 52
article thumbnail

New patent for Jazz Pharms drug XYREM

Drug Patent Watch

Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. It is available from one supplier. There are eight patents…. The post New patent for Jazz Pharms drug XYREM appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 91
article thumbnail

What are the Symptoms of Prurigo Nodularis?

Olympian Clinical Research

Prurigo nodularis is a skin condition characterized by the development of small nodular lesions, which are often severely itchy. People afflicted with this disease may develop a few lesions or potentially over 200, all of which with varying sizes. Often confused with other skin conditions, prurigo nodularis symptoms may resemble eczema or psoriasis, making it challenging to diagnose and treat. .

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Cancer Cell Line Screening: A Compass for Drug Discovery

Crown Bioscience

This article originally appeared on Labiotech.eu in July 2022 and is written by Alexander Burik. Large-panel cancer cell line screening can help find the right fit between a specific cancer cell and a therapeutic molecule, leading to the development of effective treatments. How can robust quality control, real-time screening methods, and a set of unique screening panels address current screening challenges?

article thumbnail

Diagnostic lab: from manual to automated workflows

sptlabtech

"For the last couple of years, we've been Covid testing and have been very successful with the SPT Labtech liquid handlers." Farruk Kabir | NGS Lab Manager | Aperture NextGen Laboratories Aperture NextGen Laboratories is an FDA approved CLIA lab for interdisciplinary clinical testing and research. Over the course of the pandemic, the team of around 15 to 20 lab staff based in Plano, Texas, has been busy testing for SARS-CoV-2 and developing proprietary NGS protocols.

article thumbnail

New patent for Teva Pharm drug AIRDUO RESPICLICK

Drug Patent Watch

Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are sixteen…. The post New patent for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 91
article thumbnail

Behind the AI: Synthetic Chemical Benchmarks for Testing What Structure-based AI Models Are Learning

Atomwise Blog

Our scientists have developed a set of chemical benchmarks to better understand exactly what our computational models are learning. At Atomwise, AtomNet® structure-based models can quickly identify active compounds for protein targets from large chemical libraries for drug discovery projects. Understanding how models recognize features of molecular activity can shed light on, for example, important receptor-ligand interactions, biases toward particular functional groups, or target selectivity of

Drugs 52
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Expanding the Ecosystem to Better Serve You

Advarra

The post Expanding the Ecosystem to Better Serve You appeared first on Advarra.

article thumbnail

Optimizing supplier quality management

Pharma Manufacturing

Adopting a risk-based model for inspections will flag suppliers who aren’t up to par

40
article thumbnail

New patent expiration for Eisai Inc drug LUSEDRA

Drug Patent Watch

Annual Drug Patent Expirations for LUSEDRA Lusedra is a drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this drug. This drug has…. The post New patent expiration for Eisai Inc drug LUSEDRA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 91
article thumbnail

What type of R&D efforts are needed to develop value added medicines?

Altus Drug Development

Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine? Value-added medicines are novel drug products created to provide improvements for patients that can’t be achieved using traditional therapeutic methods.

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Federal Preemption of State Attempts To Ban FDA-Approved Abortion Drugs After Dobbs

Drug & Device Law

Given what we saw in states such as Mississippi , Oklahoma , and Idaho even before the Supreme Court’s in Dobbs v. Jackson Women’s Health Org. , S. Ct. , 2022 WL 2276808 (U.S. June 24, 2022), we fully expect attempts by such states to ban FDA-approved prescription drugs that can be used to bring about abortions by chemical means. At least one state already has such a law.

article thumbnail

Engineering Angles: Crunching the data

Pharma Manufacturing

How pharma can build better facilities by leveraging digital information?

article thumbnail

New patent for Ibsa Inst drug LICART

Drug Patent Watch

Annual Drug Patent Expirations for LICART Licart is a drug marketed by Ibsa Inst Bio and is included in one NDA. The generic ingredient in LICART is diclofenac epolamine. Additional…. The post New patent for Ibsa Inst drug LICART appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 89
article thumbnail

New patent for Amicus Therap drug GALAFOLD

Drug Patent Watch

Annual Drug Patent Expirations for GALAFOLD Galafold is a drug marketed by Amicus Therap Us and is included in one NDA. There are thirty-five patents protecting this drug. This drug…. The post New patent for Amicus Therap drug GALAFOLD appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 89
article thumbnail

Which pharmaceutical companies have the most drug patents in Australia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Australia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Australia? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

New patent for Teva Pharm drug ARMONAIR RESPICLICK

Drug Patent Watch

Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 85
article thumbnail

New patent for NOVO drug WEGOVY

Drug Patent Watch

Annual Drug Patent Expirations for WEGOVY Wegovy is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are four patents protecting…. The post New patent for NOVO drug WEGOVY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 85
article thumbnail

New patent for Serenity Pharms drug NOCTIVA

Drug Patent Watch

Annual Drug Patent Expirations for NOCTIVA Noctiva is a drug marketed by Serenity Pharms Llc and is included in one NDA. There are four patents protecting this drug. Drug patent…. The post New patent for Serenity Pharms drug NOCTIVA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 85
article thumbnail

New patent for Teva Pharm drug ARMONAIR DIGIHALER

Drug Patent Watch

Annual Drug Patent Expirations for ARMONAIR+DIGIHALER Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are twenty…. The post New patent for Teva Pharm drug ARMONAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 84
article thumbnail

New patent for Teva Branded drug PROAIR RESPICLICK

Drug Patent Watch

Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 81
article thumbnail

New patent expiration for NOVO drug SAXENDA

Drug Patent Watch

Annual Drug Patent Expirations for SAXENDA Saxenda is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are twenty-three patents protecting…. The post New patent expiration for NOVO drug SAXENDA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 81
article thumbnail

New patent for Teva Branded drug AUSTEDO

Drug Patent Watch

Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are seven…. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 79
article thumbnail

New patent for Teva Pharm drug AIRDUO DIGIHALER

Drug Patent Watch

Annual Drug Patent Expirations for AIRDUO+DIGIHALER Airduo Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are twenty-three…. The post New patent for Teva Pharm drug AIRDUO DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 78
article thumbnail

New patent expiration for NOVO drug SAXENDA

Drug Patent Watch

Annual Drug Patent Expirations for SAXENDA Saxenda is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are twenty-three patents protecting…. The post New patent expiration for NOVO drug SAXENDA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 77
article thumbnail

New patent for Hope Pharms drug NITHIODOTE

Drug Patent Watch

Annual Drug Patent Expirations for NITHIODOTE Nithiodote is a drug marketed by Hope Pharms and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for Hope Pharms drug NITHIODOTE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 77